

Adjuvant brachytherapy for Stage IB Grade 2 endometrial carcinoma: Multivariate analysis of a single institution experience

Margarita Tokar,

Michael Meirovich¹,

Dmitri Bobilev,

Wilmosh Mermershtain

Department of Oncology, ¹Division of Obstetrics and Gynecology, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Address for correspondence:

Dr. Wilmosh Mermershtain,
Department of Oncology, Soroka University Medical Center,
P.O. Box 151, Beer-Sheva 84101, Israel.
E-mail: wilmosh@bgu.ac.il

INTRODUCTION

Endometrial cancer is the fourth most common female malignancy and is the most common gynecological cancer in the United States. In 2006, an estimated 41,200 new cases occurred, accounting for approximately 6% of diagnosed female cancers. Endometrial cancer was estimated to have resulted in 3% of female cancer deaths in 2006.^[1]

However, the optimal adjuvant treatment for early-stage endometrial carcinoma remains undefined despite published results from randomized trials.^[2] Recent publications have revealed 5-year overall survival (OS) rates of 80% to 90% for women with stage I disease who underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) and adjuvant radiation therapy (XRT).^[3] Controversy exists over how XRT should be administered in the patients with stage I endometrial cancer. Numerous reports have focused on early-stage patients treated with postoperative XRT. These reports vary greatly. In some intravaginal brachytherapy (IVRT) is used while, in others, all patients undergo pelvic irradiation therapy (PRT). Despite such differences, pelvic/

ABSTRACT

Objective: The aim was to investigate the value of postoperative brachytherapy for patients with Stage IB, Grade 2 endometrial carcinoma. **Patients and Methods:** Forty-six patients with Stage IB, Grade 2 endometrial carcinoma, were treated with simple hysterectomy and bilateral oophorectomy in our institution. The mean age was 63 (range, 42-81). Surgical staging, defined as peritoneal washing and pelvic lymph node sampling was performed in 73% of patients. Twenty-two patients (47%) received a postoperative intravaginal brachytherapy (IVRT), and 24 patients (53%) were followed-up without additional treatment. **Results:** The median follow-up was 60 months. The 5-year overall survival for irradiated and nonirradiated patients, was 83.5 and 94.7%, respectively. Four patients (8.7%) developed relapse, two in the group of postoperative IVRT and 2 in the follow-up only group. Multivariate analysis demonstrated a borderline association ($P = 0.06$) between lower uterine segment involvement and poor pelvic-vaginal control. The presence of GOG #99 high-risk features did not affect the pelvic control rate. **Conclusion:** According to our experience and previously published data, most patients with FIGO Stage IB, Grade 2 endometrial carcinoma may be cured with surgery alone.

Key words: Adjuvant brachytherapy, endometrial adenocarcinoma, endometrium, radiotherapy

vaginal control rates exceed 95% in the great majority of reports.

Patients with Stage IB Grade 2 endometrial cancer are considered to have low-risk disease. Although some investigators recommend no postoperative treatment, others favor adjuvant radiotherapy, either PRT or IVRT.

The purpose of this study was to evaluate the impact of adjuvant IVRT on local control and survival for patients with Stage IB Grade 2 endometrial cancer, after TAH-BSO.

PATIENTS AND METHODS

The patient population consisted of 46 patients with FIGO Stage IB Grade 2 (moderately differentiated) endometrial cancer, who were treated at the Soroka Medical Center between February 1990 and October 2001. All patients had endometrial adenocarcinoma FIGO Stage IB Grade 2. Patients with any component of papillary serous or clear cell histology were excluded from our analysis.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Tokar M, Meirovich M, Bobilev D, Mermershtain W. Adjuvant brachytherapy for Stage IB Grade 2 endometrial carcinoma: Multivariate analysis of a single institution experience. Indian J Med Paediatr Oncol 2016;37:112-5.

Access this article online

Quick Response Code:



Website:
www.ijmpo.org

DOI:
10.4103/0971-5851.180148

The mean age was 63 (range, 42-81), [Table 1].

All patients underwent TAH-BSO. Pelvic washings were obtained in 40 patients (87%). Surgical staging, defined as pelvic washings and pelvic lymph node sampling, was performed in 33 patients (72%). The indications for surgical staging were generally determined by the depth of invasion and the tumor grade.

Twenty-two (47%) patients received postoperative low-dose rate intravaginal radiotherapy (LDR-IVRT), and 24 (53%) had received no further treatment.

The total dose of postoperative LDR-IVRT was 8 Gy, delivered in two fractions over a 2 week interval. The target volume treated was one-half to two-thirds of the length of the vagina. The treatment was delivered using a cylinder loaded by ¹³⁷Cs source. The typical dose per fraction was 4 Gy. The dose was prescribed to a depth of 0.25 cm from the vaginal surface. The median follow-up time was 60 months.

Survival rates were calculated using the Kaplan–Meier method. Independent prognostic factors for survival were analyzed using the Cox proportional hazards model. The probability of relapse was estimated using logistic regression model.

RESULTS

After a median follow-up of 5-year (range, 0.5-15.1 years), 38 (82.6%) of the 46 patients were alive.

Four patients (8.7%) developed relapse, two in the group of postoperative IVRT and two in the follow-up only group. Their clinical, pathological, and treatment characteristics are shown in Table 2. The site of relapse was the vaginal vault in 2 patients (4.4%), the pelvis in one patient (2.2%) and combined pelvic/distant in 1 patient (2.2%). Two isolated vaginal vault recurrences were successfully controlled by PRT alone and both women are alive with stable disease. One patient with pelvic/distant disease received PRT and systemic chemotherapy, but eventually died with progressive disease.

The estimated 5-year survival for the irradiated and nonirradiated groups was 83.52 and 94.74%, respectively [Figure 1]. Log-rank analysis of survival showed no significant difference between the irradiated (mean: 10.6 years; 95% CI, 8.4/12.7) and nonirradiated groups of the patients (mean: 12.8 years; 95% CI, 10.7/14.9; $P = 0.45$).

The GOG #99 studies defined a number of risk factors for early-stage endometrial cancer such as age, lymph – vascular space invasion (LVI), depth of myometrial invasion and Grade 2 or 3 tumors. The depth of myometrial invasion and the tumor grade were predetermined in our study. LVI, age, lower uterine segment involvement and distance from serosa were

Table 1: Patient characteristics

Characteristic	Number (%)
Stage IB	46 (100)
Grade 2	46 (100)
Peritoneal washing	40 (86.9)
CSS	33 (71.7)
Positive LVI	15 (32.6)
Lower uterine segment involvement	13 (28.3)
Distance from serosa, <1 cm	15 (32.6)
Relapsed patients	4 (8.7)

CSS – Cancer specific survival; LVI – Lymphovascular invasion

Table 2: Characteristics of relapsed patients

Age	LVI	SqM	LS	DS (cm)	XRT	Relapse	Latest status	Follow-up (months)
57	-	+	+	1.40	HDR	pelvic	Dead	54
58	+	+	+	0.72	—	vault	Alive	97
60	-	+	-	0.80	HDR	pelvic+distant	Dead	28
77	-	+	+	0.80	—	vault	Alive	84

LVI – Lymphovascular invasion; SqM – Squamous metaplasia; LS – Lower segment; DS – Distance from serosa; XRT – Radiation therapy; HDR – High-dose-rate




Figure 1: Kaplan–Meier curves for overall survival by radiation therapy

analyzed for relationship with survival time using Cox proportional hazards model. Hazard ratio estimates for each prognostic factor are shown in Table 3. No, statistically significant effect on survival was detected. Postoperative IVRT was also shown to have no prognostic significance in terms of local control and survival.

Logistic regression model showed that postoperative IVRT or patient's age, LVI, lower uterine segment involvement, distance from serosa did not significantly affect pelvic relapse rate. Multivariate analysis demonstrated a borderline association between lower uterine segment involvement and poor pelvic-vaginal control (or, 14.7; 90% CI, 1.39/154.73; $P = 0.06$) [Table 4].

DISCUSSION

The role of adjuvant PRT in early-stage endometrial cancer was evaluated in two large randomized trials. To

determine which groups of patients are at high-risk of recurrence, GOG #99 separated the patient population into high-risk versus low-risk, according to advanced age, Grade 2 or 3 tumors, lymph-vascular invasion and outer one-third myometrial invasion.^[4] Nearly 60% of patients in the GOG #99 trial were Stage IB, and approximately 80% had Grade 1 or 2 disease. The Postoperative Radiation Therapy in Endometrial Cancer trial included 715 patients with stage 1C, Grade 1 or 2, and Stage IB, Grade 2 or 3 endometrial cancer.^[5] A total of 221 (30%) patients with stage 1B Grade 2 were evaluated in this trial. These two randomized trials concluded that PRT for stage I endometrial cancer leads to improved loco-regional control but had no impact on OS.

Many series have reported an excellent outcome in Stage IB Grade 1 or 2 disease without adjuvant XRT.^[6-8] In surgically staged patients, Straughn, *et al.*^[8] reported a 3.7% overall failure rate in 296 patients, with 64% of the recurrences being at the vaginal vault. Other series have reported similar outcomes in patients who did not undergo surgical staging. The Mayo clinic reported their experience in 261 patients with Grade 1 or 2 and Stage IB disease treated with surgery alone. There was only a 2% isolated local recurrence rate without adjuvant XRT.^[7] Given the low-risk of pelvic failure, some investigators recommended IVRT as adjuvant treatment for this group of patients.^[9,10] The largest series was reported by Alektiar *et al.*^[11] In 233 patients without surgical staging there was an overall 4% relapse rate, only 2% failed in the pelvis.

Taken together, these data do not support the use of postoperative pelvic XRT for the low-risk patients. Observation alone is appropriate for Stage IB Grade 1

disease and observation or IVRT is a reasonable treatment option for Stage IB, Grade 2 disease.

Recently, a large population analysis of adjuvant XRT in early-stage endometrial cancer was published.^[3] This study included 21 249 women with Stage IA-IC endometrial cancer. A total of 4080 (19.2%) women received postoperative XRT. Of these patients, 2551 (62.5%) had pelvic XRT, 732 (17.9%) had IVRT, and 1078 (26.4%) received combination of EBRT with IVBT. Of 4316 patients with Stage IB Grade 2, 751 (17.4%) received adjuvant XRT. The authors concluded that adjuvant XRT has no impact on OS for this group of patients, except the patients older than age 75 years old.

The results of the present study suggest that postoperative IVRT has no significant impact on local control and survival of patients with Stage IB Grade 2 endometrial cancer.

Based on our experience and previous publication the surgically staged patients with Stage IB Grade 2 endometrial cancer without additional risk factors may be treated with TAH-BSO without postoperative XRT.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, *et al.* Cancer statistics, 2006. *CA Cancer J Clin* 2006;56:106-30.
2. Shaeffer DT, Randall ME. Adjuvant radiotherapy in endometrial carcinoma. *Oncologist* 2005;10:623-31.
3. Lee CM, Szabo A, Shrieve DC, Macdonald OK, Gaffney DK. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. *JAMA* 2006;295:389-97.
4. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, *et al.* A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A gynecologic oncology group study. *Gynecol Oncol* 2004;92:744-51.
5. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, *et al.* Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. *PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet* 2000;355:1404-11.
6. Carey MS, O'Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, *et al.* Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. *Gynecol Oncol* 1995;57:138-44.
7. Poulsen HK, Jacobsen M, Bertelsen K, Andersen JE, Ahrons S, Bock JE, *et al.* Patients with early stages of endometrial cancer should be spared adjuvant radiotherapy. *Danish Endometrial Cancer Group. Ugeskr Laeger* 1997;159:3403-7.
8. Straughn JM Jr, Huh WK, Kelly FJ, Leath CA 3rd, Kleinberg MJ, Hyde J Jr, *et al.* Conservative management of

Table 3: Relationship of adverse prognostic factor with survival

Survival time on	Hazard ratio	P value	95% CI
Age	1.05	0.413	0.93-1.19
No IVRT	0.56	0.475	0.11-2.78
LVI	0.48	0.518	0.05-4.36
Low distance from serosa (<1 cm)	0.87	0.867	0.16-4.65
Lower uterine segment involvement	0.34	0.355	0.03-3.38

LVI – Lymphovascular invasion; IVRT – Intravaginal radiotherapy; CI – Confidence interval

Table 4: Regression analysis of association between patient parameters and risk of recurrence

Parameters in relapsed patients	Odds ratio	P value	90% CI
Age	0.93	0.331	0.82-1.05
No IVRT	1.25	0.869	0.14-11.43
LVI	0.29	0.435	0.02-3.86
Lower uterine segment involvement	14.70	0.06	1.39-154.74
Low distance from serosa (<1 cm)	8.55	0.156	0.71-103.05

LVI – Lymphovascular invasion; IVRT – Intravaginal radiotherapy; CI – Confidence interval

- stage I endometrial carcinoma after surgical staging. *Gynecol Oncol* 2002;84:194-200.
9. Anderson JM, Stea B, Hallum AV, Rogoff E, Childers J. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. *Int J Radiat Oncol Biol Phys* 2000;46:417-25.
 10. MacLeod C, Fowler A, Duval P, D'Costa I, Dalrymple C, Firth I, *et al.* High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. *Int J Radiat Oncol Biol Phys* 1998;42:1033-9.
 11. Alektiar KM, McKee A, Venkatraman E, McKee B, Zelefsky MJ, Mychalczak BR, *et al.* Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. *Int J Radiat Oncol Biol Phys* 2002;53:707-13.